Engine Biosciences Pte. Ltd., a Singapore and Silicon Valley-based company using machine learning, combinatorial genetics and other technologies to hasten the discovery of gene interactions and biological networks underlying disease, has raised $43 million in series A financing. Polaris Partners led the round, which the company said would help it expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs, and scale its technology platform.

PARIS – French public sector investment bank Bpifrance SA is consolidating its commitment to e-health startups, with the announcement of a doubling in size of its Fonds Patient Autonome [Patient Independence Fund] to more than $120 million. Three further partners from France have also subscribed to this new fund. These are the Banque des Territoires – an offshoot of the French national public sector savings and investment fund, Caisse des Dépôts et Consignations; the Harmonie Mutuelle insurance group; and the foundation hospitals Groupe Vivalto Santé SA.

TORONTO – Arthrolense Inc. has just seen its bank balance swell after Lynx Equity Ltd. invested $2 million to further develop the startup’s augmented, mixed reality surgical guidance systems for hip and knee replacement. According to orthopedic surgeon and company CEO David Backstein the Arthrolense system uses vastly improved hologram-based technologies to solve problems that persist in computer navigation and robotic systems.

LONDON – Pulmocide Ltd. has closed a $92 million oversubscribed series C, providing the means to take its inhaled antifungal drug, PC-945, through a global phase III registration study in invasive pulmonary aspergillosis.